Oppenheimer Asset Management Inc. Acquires 920 Shares of Smith & Nephew plc (NYSE:SNN)

Oppenheimer Asset Management Inc. grew its stake in shares of Smith & Nephew plc (NYSE:SNN) by 5.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,218 shares of the medical equipment provider’s stock after buying an additional 920 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Smith & Nephew were worth $536,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Ashton Thomas Securities LLC grew its position in Smith & Nephew by 8.4% during the 3rd quarter. Ashton Thomas Securities LLC now owns 69,849 shares of the medical equipment provider’s stock worth $2,175,000 after acquiring an additional 5,385 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Smith & Nephew by 63.7% in the third quarter. Crossmark Global Holdings Inc. now owns 112,859 shares of the medical equipment provider’s stock worth $3,515,000 after purchasing an additional 43,924 shares during the last quarter. River Road Asset Management LLC bought a new position in shares of Smith & Nephew in the third quarter worth approximately $38,588,000. QRG Capital Management Inc. increased its stake in shares of Smith & Nephew by 3.5% in the third quarter. QRG Capital Management Inc. now owns 89,013 shares of the medical equipment provider’s stock worth $2,772,000 after buying an additional 3,017 shares during the period. Finally, US Bancorp DE raised its holdings in Smith & Nephew by 19.2% during the 3rd quarter. US Bancorp DE now owns 11,167 shares of the medical equipment provider’s stock valued at $348,000 after buying an additional 1,802 shares during the last quarter. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew Stock Down 0.1 %

Shares of NYSE SNN opened at $25.51 on Wednesday. The firm has a fifty day simple moving average of $28.49 and a two-hundred day simple moving average of $27.89. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. Smith & Nephew plc has a 12 month low of $23.65 and a 12 month high of $31.72.

Analyst Ratings Changes

A number of equities analysts have issued reports on SNN shares. Berenberg Bank cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Wednesday, November 6th. Deutsche Bank Aktiengesellschaft downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, StockNews.com cut Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.